Clinical Trials in Tennessee

Showing 11121-11140 of 15,329 trials

Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment

NCT02471222

This is a multi-center, randomized, double-blind, placebo-controlled, 2-arm, parallel group study of ADS-5102 extended release (ER) capsules, an investigational formulation of amantadine, dosed once daily at bedtime for the treatment of walking impairment in MS. ADS-5102 is designed to be administered once daily at bed time, ADS-5102 achieves higher plasma amantadine concentrations in the early morning, sustained throughout the afternoon, and lower concentrations in the evening when patients are sleeping. ADS-5102 is designed to deliver its primary treatment effect during the day, and potentially reduce the adverse events of immediate-release amantadine when the patient is asleep.

Walking ImpairmentMultiple Sclerosis

Adamas Pharmaceuticals, Inc.60 participantsStarted May 2015

Phoenix, Arizona, United States • Aurora, Colorado, United States • Sarasota, Florida, United States +12 more locations

COMPLETEDPhase 321 miles

The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial

NCT01000727

This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or urgent coronary revascularization (e.g. medical procedures performed to restore the normal blood flow in patients with atherosclerosis)) when treatment is started within 30 days after an acute coronary syndrome (also called ACS).

Acute Coronary Syndrome

GlaxoSmithKline13,026 participantsStarted Dec 2009

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Huntsville, Alabama, United States +911 more locations

Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment

The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial

Find Trials by Condition in Tennessee

A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma

Safety Study to Evaluate FluMist in Immunocompromised Children

A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors

Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function

Safety and Adherence of a Non-medicated Intravaginal Ring (IVR)

Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment

Multi-Center Comparative Trial of the ASR™-XL Acetabular Cup System vs. the Pinnacle™ Metal- on- Metal Total Hip System

HeRO Vascular Access Device Bacteremia Study

A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis

Biomarkers of Mild and Moderate Traumatic Brain Injury

Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery

Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy

Proteogenomic Biomarker Panels in a Serial Blood & Urine Monitoring Study of Kidney Transplant Recipients

Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease

A Safety Study of CNTO 2476 in Patients With Age-Related Macular Degeneration

Effect of VPro5 Therapy on Clear Aligner Therapy

PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)